Pharmacist’s Letter | Clinical Updates, CE & Recommendations You Can Trust

February 2026 Issue

Explain How New ORAL Semaglutide Stacks Up for Weight Loss

Patients are asking about Rx semaglutide tablets (Wegovy), the first ORAL GLP-1 agonist FDA approved for obesity and overweight...

Resources

Chart: GLP-1 and GIP/GLP-1 Receptor Agonist Interactive Comparison Chart
Chart: Comparison of Weight Loss Products

Be Prepared With Guidance About Childhood Immunizations

Changes to the CDC childhood vaccine schedule are causing confusion...

Set the Record Straight With Menopausal Hormone Therapy

Patients will ask you about menopausal hormone therapy (MHT)...

Lift the Fog Around Fibromyalgia Treatment

New sublingual cyclobenzaprine (Tonmya) raises questions about managing fibromyalgia symptoms such as pain, mood, and sleep issues...

GO TO FULL ISSUE

CE & Training

INTERACTIVE SELF-STUDY CE: Substance Use Disorders and Pain Management: MATE Act Training

CE IN THE LETTER: Pharmacist's Letter February 2026

LIVE CE: Pharmacy Essential Updates February 2026

PODCAST CE: Medication Talk - Smoking and Vaping Cessation

GO TO CE & TRAINING ORGANIZER >

Featured Clinical Resources

GLP-1 and GIP/GLP-1 Receptor Agonists interactive chart

Free CE for Pharmacists

Pharmacist's Letter offers ACPE-accredited CE at no charge to help pharmacists meet license renewal requirements. Claim your free CE now:

Group Purchases & Pricing

Pharmacist’s Letter is eligible for bulk discounts. Customize CE and compliance training assignments. Easily manage users and run reports. Bundle with other products for significant savings. Request information